

PTO/SB/21 (09-04)
Approved for use through 07/31/2008, OMB 0651-0031
S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

:- Linder the Denemant Res	tiirtion Act of 1995, no person	U.S	. Patent and T	rademark Office:	J.S. DEPARTMENT OF COMMERCE. displays a valid OMB control number.	
The state of the s		Application Number	1	10/797,558		
TRANSMITTAL		Filing Date	March 10,	March 10, 2004		
FORM		First Named Inventor	NAREAK	NAREAK DOUK et al.		
		Art Unit	3731			
(to be used for all correspondence after initial filing)		Examiner Name	TRUONG,	TRUONG, Kevin T.		
Total Number of Pages in This Submission		Attorney Docket Number	PA563 DR	PA563 DIV1		
ENCLOSURES (Check all that apply)						
Fee Transmittal For	m   🔲	Drawing(s)		Anser /	Allowance Communication to TC	
Fee Attache	ttached Licensing-related Papers				al Communication to Board beals and Interferences	
	la	Petition			ol Communication to TC	
		etition to Convert to a			ni Notice, Brief, Reply Brief)	
		rovisional Application			etary information	
		Change of Correspondence Address		السببيا	Letter Enclosure(s) (please Identify	
Extension of Time Request		Terminal Disclaimer		below		
Express Abandonment Request				2nd Preimir Postcard	ary Amendment and Return	
Information Disclosu	CD, Number of CD(s)	····				
	_	Landscape Table on C	CC CIC			
Certified Copy of Priority Remark						
Document(s)						
Reply to Missing Parts/ Incomplete Application						
Reply to Missing Parts under 37 CFR 1.52 or 1.53						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Name						
Medtronic Vascular, Inc.						
Signature Janu F. Coro						
Printed name James F. Crittenden						
Date February 7, 2005			Reg. No.	0. 39,563		
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:						
Signature	11/2 12	2				
Typed or edited same	(Imberty Melvin			Date	February 7, 2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## CERTIFICATE OF MAILING (37 C.F.R. § 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in the envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 7, 2005.

By: Kimberly Melvin

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

10/797,558

Confirmation No.:

4400

**Applicant** 

NAREAK DOUK, et al.

Filed

March 10, 2004

TC/A.U.

3731

Examiner

Truong, Kevin T.

Docket No.

PA563 DIV 1

Customer No.

28390

Title

TEMPORARY INTRALUMINAL FILTER GUIDEWIRE

Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **SECOND PRELIMINARY AMENDMENT**

Sir:

In addition to the preliminary amendment filed March 10, 2004, please amend the above-identified application as set forth below.

Amendments to the Claims are reflected in the listing of claims which begin on page two (2) of this paper.

Remarks begin on page five (5) of this paper.